Industry: Healthcare
Published Date: September-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 232
Report ID: PMRREP33154
Worldwide revenue from the bioinks market reached US$ 115.7 Mn in 2021, with the global market estimated to surge ahead at a CAGR of 18.6% to climb to a market size of US$ 738.2 Mn by the end of 2032.
Sales of bioinks accounted for 8.9% revenue share of the global 3D bioprinting market in 2021.
| Report Attritube | Details |
|---|---|
|
Bioinks Market Size (2022) |
US$ 134.2 Mn |
|
Projected Market Value (2032) |
US$ 738.2 Mn |
|
Global Market Growth Rate (2022-2032) |
18.6% CAGR |
|
Market Share of Top 5 Countries |
61.2% |
The global market for bioinks expanded at a CAGR of 12.6% from 2017 to 2021.
Bioinks are biomaterial used to produce engineered-artificial live tissues using 3D printing. Various bioinks derived from natural or synthetic sources such as hyaluronic acid, gelatin, alginate, collagen, agarose, poly (ethylene glycol) diacrylate (PEGDA), and graphene play an important role in organ development and skin regeneration.
Growing use of bioinks in the field of tissue engineering, tissue transplant, and pharmaceutical drug development is expected to favor market expansion. Moreover, Companies are investing heavily in R&D to expand their product portfolios and market presence globally, especially to cater to the developing needs of researchers.
3D bioprinting technology with bioinks has been used in regenerative medicine, cancer drug therapy, and medical device manufacturing. The adoption of this technology and an increase in research and development activities with bioinks will also boost the market.
Currently, researchers are testing bioinks to develop 3D printed cartilages, bones, and vital organs. A key component of 3D bioprinting is bioinks, which are crucial for the development of functional organs or tissue structures.
Government initiatives focused on innovation in 3D technology directly drive the demand for bioinks. Such initiatives are expected to enhance standards and will help in finding gaps in the industry, which will drive bioinks market growth.
The global bioinks market is expected to surge ahead at 18.6% CAGR and reach a market size of US$ 738.2 Mn by the end of 2032.
Increasing Cases of Organ Failure Driving Demand for 3D Printed Organs
Increasing cases of organ failure due to several reasons such as unhealthy lifestyles, accidents, aging, and burns are leading to a rise in the sales of bioinks as a result of the tremendous need for 3D printed organs. The 3D bioprinting method is a possible way to overcome the existing organ shortage crisis across the world. Currently, no drug therapy is available to reverse organ failure.
The bones are a crucial component in orthopedic treatment and surgeries. Organ transplant is in demand due to the rise in accidents and prevalence of osteoporosis, globally. A major clinical challenge in craniomaxillofacial (CMF) and orthopedic surgery is the development of correctly sized bones. In such cases, 3D bioprinted bones and cartilages are helpful.
The requirement for biocompatible and durable organs is expected to shift conventional procedures to tissue engineering with 3D bioprinting techniques, thereby boosting the revenue of the bioinks industry.
Intellectual Property and Ethical Considerations
Intellectual property rights and strict guidelines for patent filing are major restraining factors for the market. Ethical, religious, and moral concerns are expected to be elevated by synthetically developed human body organs with the help of 3D printing and intellectual property clearance.
Advancements in 3D printing have been associated with intellectual property theft and are expected to create major challenges in the future. Furthermore, to receive FDA approval, implanted devices must undergo the process of approval filing in specific countries. The rising failure rate of FDA filings for such devices presents a negative outlook for market growth.
Moreover, the biocompatibility of materials used in 3D bioprinting is a major concern in tissue engineering and organ transplants, where allergic reactions and life-threatening situations need to be avoided.
How is the U.S. Bioinks Market Being Driven?
High Incidence of Accidental Case Trauma
The U.S. accounted for 95% share of the North American bioinks market in 2021.
The market is anticipated to develop because of an increase in awareness about personal care. An increasing number of dermal procedures and skin transplants across the U.S. is the result of growing consumer awareness about personal appearance and increasing personal disposable income. Growing awareness about self-care is among the major factors driving the consumption of bioinks in a developed country such as the U.S.
Thus, the demand for bioinks has increased in the U.S. due to research and development activities related to organ development.
Why is Germany a Lucrative Market for Bioink Providers?
High Patient Compliance & Availability of Healthcare Professionals
Germany held 28.1% share of the European market for bioinks in 2021.
Growing adoption of 3D bioprinted products derived from bioinks among the aging population of Germany is expected to drive the market. The risk of peripheral diabetes-related gangrene, vascular disease, and osteoarthritis is higher among the elders. An increasingly aging population with organ failure can directly boost the revenue growth of the bioinks market in the country.
What’s Supporting Bioinks Market Expansion in China?
Huge Government Investments in Biotech R&D
The market in China is predicted to expand at a CAGR of 19.4% from 2022 to 2032.
The Chinese government is striving to achieve independence in the biopharma field and one of the country's top priorities is to expand the biopharmaceutical business. The government is investing billions in biotech research and development.
Official estimates show that scientific R&D spending reached US$ 291 billion in 2018 or a little over 2% of its GDP, and the government plans to spend even more this year (2.5% of GDP). This increasing spending by the government on biotech research and development is promoting the growth of the market in the country.
Which Material is Most Widely Used in Bioinks?
High Demand for Biocompatible Materials
The collagen segment held the largest share of 20.3% of the bioinks market in 2021.
The basis of collagen bioinks is a collagen hydrogel, collagen I, which is a major structural component of the skin, bone, tendon, and other connective tissues. Collagen has the property of easy compatibility and generates a fibrous network in the human body. Therefore, due to its advanced properties, it is widely used and is set to present optimistic growth prospects for market players.
Which Printing Modality Accounts for Greater Adoption Of Bioinks?
“High Flexibility Makes Extrusion-based Bioprinting Hugely Popular”
Extrusion-based bioprinting accounts for the highest market share of 73.4% with a market value of US$ 98.9 Mn at the end of 2021.
Extrusion-based bioprinting is a technique that is used to manufacture objects in a layer-by-layer manner as per computer-aided design (CAD) data. It has great flexibility in printing various biological products such as tissue constructs, cells, microfluidic devices, tissues, and organ modules. High adoption of this technique from research and pharmaceutics to clinics is set to provide the segment with high growth traction over the forecasted years.
Which Application Accounts for Greater Adoption Of Bioinks?
Tangible Shift towards Regenerative Therapies
Tissue engineering & regenerative medicine application held a high market share of 60.4% in 2021.
Cell and gene therapies are modalities of regenerative medicine and are considered one of the most promising disciplines in the field of modern science and medicine platforms. Thus, the growing number of potentially effective and safe therapies has led to a tangible shift toward regenerative therapies, which is eventually anticipated to drive the need for bioinks over the coming years.
Leading bioink manufacturers are developing technologically advanced products. Correspondingly, major competitors in the industry are engaged in merger and acquisition strategies to enhance their product offerings. Moreover, companies are also focusing on the expansion of corporate collaborations to boost their overall revenue.
For instance:
|
Attribute |
Details |
|---|---|
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2017-2021 |
|
Market Analysis |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
By Material:
By Source:
By Printing Modality:
By Application:
By Organ:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global bioinks market was worth US$ 115.7 Mn at the end of 2021.
The market for bioinks is expected to register 18.6% CAGR over the forecast period.
Increasing adoption of 3D printing, rising demand for biocompatible medical implants, and new frontiers in regenerative healthcare are key trends in this market.
The U.S., Germany, India, Australia, and U.K. account for the most demand for bioinks.
The U.S. accounted for 40.8% share of the global bioinks market in 2021.
Sales of bioinks in Europe are expected to increase at 17.7% CAGR through 2032.
The U.S., U.K., and Germany are prominent manufacturers of bioinks.
CELLINK (BICO GROUP AB), Merck KGaA, Collplant Biotechnologies Ltd., UPM Biomedicals, Allevi, Inc., Humabiologics, Foldink, and Black Drop Biodrucker Gmb are major bioink manufacturers.
